PRIMA implant helps first Stargardt patient read a word
Science Corporation says its PRIMA retinal implant helped the first patient with Stargardt disease recognise a letter and read a word during rehabilitation.
PRIMA, Science Corporation’s retinal implant, has been placed in its first patient with Stargardt disease, an inherited condition that progressively damages central vision, according to TechCrunch.1 The company says the patient saw a letter during the first rehabilitation session and read a word during the second.1
What happened
Science Corporation CEO Max Hodak announced the milestone at TechCrunch Disrupt. The patient received the implant in May as part of an ongoing trial at Sydney Eye Hospital in Australia.1 Stargardt disease currently has no cure, and the company says roughly 150,000 people worldwide have lost vision because of it.1
PRIMA is already commercially available in Europe for people with geographic atrophy, an advanced form of age-related macular degeneration. Its use for Stargardt disease remains part of the company’s clinical work rather than an approved treatment.12
How the implant works
The system combines a tiny implant with camera-equipped glasses. The glasses transmit a view of the world to the implant, which sits beneath the retina where light-sensing cells have degenerated. The implant then acts like an artificial set of photoreceptors.1
The device used by the first Stargardt patient measures 2mm by 2mm. It currently provides a small, black-and-white, high-contrast patch of vision — more like looking through a straw than seeing a full scene. Science Corporation says the next generation is intended to increase the field of view and detail.1
Science’s official PRIMA materials describe the implant as a light-powered device designed to stimulate surviving retinal cells, working alongside specialised glasses that provide power and visual data.2
Our opinion
This is a meaningful clinical milestone, but it is not a restoration of normal sight. The early result — recognising a letter and then reading a word — is promising precisely because the device is still limited: the current system offers a narrow, monochrome view and remains under evaluation for Stargardt disease. The next important evidence will be whether more patients can use that limited signal consistently in daily life, and whether later versions widen the visual field without sacrificing clarity.
For now, PRIMA is best understood as an experimental bridge between damaged photoreceptors and the brain, not a finished replacement for sight.